I last covered Seaport Therapeutics (SPTX) about two and a half months ago. Since then, the GlyphAllo driving study has read out cleanly, the GlyphAgo Phase 2a has dosed its first patient, and the shares have swung
Trending
- Bayer wins Roundup weedkiller most cancers trial whereas awaiting settlement ruling
- We’re Dropping the Cognitive House Race
- UK-Nigeria Remittance Rivals Battle on Charges and Banking Options
- A single mind sign could clarify schizophrenia's most puzzling signs
- El-Sayed's Father Related to Charity As soon as Accused of Financially Aiding Saddam Hussein
- Perhaps This Time, the GOP Will Confront Defeat
- Banco Comercial Português, S.A. (BPCGY) Q3 2026 Earnings Name Transcript
- Fifty Years In the past, Milton Friedman Upended Financial ‘Experience’
Oldest New York Newspaper Brand Est. 1725